(Q46393889)

English

The immunogenicity-enhancing effect of emulsion vaccine adjuvants is independent of the dispersion type and antigen release rate--a revisit of the role of the hydrophile-lipophile balance (HLB) value

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

21 December 2017

http://europepmc.org/abstract/MED/15780450

The immunogenicity-enhancing effect of emulsion vaccine adjuvants is independent of the dispersion type and antigen release rate--a revisit of the role of the hydrophile-lipophile balance (HLB) value (English)

1 reference

Europe PubMed Central

PubMed publication ID

21 December 2017

http://europepmc.org/abstract/MED/15780450

author name string

Ya-Wun Yang

1

1 reference

Europe PubMed Central

PubMed publication ID

21 December 2017

http://europepmc.org/abstract/MED/15780450

An-Chi Wei

2

1 reference

Europe PubMed Central

PubMed publication ID

21 December 2017

http://europepmc.org/abstract/MED/15780450

Shan-Shan Shen

3

1 reference

Europe PubMed Central

PubMed publication ID

21 December 2017

http://europepmc.org/abstract/MED/15780450

language of work or name

0 references

publication date

1 April 2005

1 reference

Europe PubMed Central

PubMed publication ID

21 December 2017

http://europepmc.org/abstract/MED/15780450

number of pages

11

1 reference

based on heuristic

inferred from page(s)

1 reference

Europe PubMed Central

PubMed publication ID

21 December 2017

http://europepmc.org/abstract/MED/15780450

23

1 reference

Europe PubMed Central

PubMed publication ID

21 December 2017

http://europepmc.org/abstract/MED/15780450

20

1 reference

Europe PubMed Central

PubMed publication ID

21 December 2017

http://europepmc.org/abstract/MED/15780450

2665-2675

1 reference

Europe PubMed Central

PubMed publication ID

21 December 2017

http://europepmc.org/abstract/MED/15780450

T-cell adjuvants

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.09.007

7 January 2021

Recent advances in vaccine adjuvants

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.09.007

7 January 2021

MF59-adjuvanted vaccines: increased immunogenicity with an optimal safety profile

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.09.007

7 January 2021

European union regulatory developments for new vaccine adjuvants and delivery systems

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.09.007

7 January 2021

Challenges in the development of effective peptide vaccines for cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.09.007

7 January 2021

Immunological aspects of controlled antigen delivery

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.09.007

7 January 2021

Determinants of release rate of tetanus vaccine from polyester microspheres.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.09.007

7 January 2021

Controlled protein delivery from biodegradable tyrosine-containing poly(anhydride-co-imide) microspheres

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.09.007

7 January 2021

Polymeric lamellar substrate particles for intranasal vaccination

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.09.007

7 January 2021

Poly-D,L-lactide-co-poly(ethylene glycol) microspheres as potential vaccine delivery systems

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.09.007

7 January 2021

Squalene and squalane emulsions as adjuvants

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.09.007

7 January 2021

A simple and rapid vortex method for preparing antigen/adjuvant emulsions for immunization

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.09.007

7 January 2021

The rational design of vaccine adjuvants for mucosal and neonatal immunization

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.09.007

7 January 2021

Induction of cell death by saponin and antigen delivery

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.09.007

7 January 2021

The apoptotic and necrotic effects of tomatine adjuvant

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.09.007

7 January 2021

Cell death induced by vaccine adjuvants containing surfactants

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.09.007

7 January 2021

Development and application of PROVAX adjuvant formulation for subunit cancer vaccines

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.09.007

7 January 2021

Immunogenicity of chi4127 phoP- Salmonella enterica serovar Typhimurium in dogs

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.09.007

7 January 2021

Novel aggregate structure adjuvants modulate lymphocyte proliferation and Th1 and Th2 cytokine profiles in ovalbumin immunized mice

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.09.007

7 January 2021

Evaluation of novel aggregate structures as adjuvants: composition, toxicity studies and humoral responses

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.09.007

7 January 2021

Induction of antigen-specific class I-restricted cytotoxic T cells by soluble proteins in vivo

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.09.007

7 January 2021

Generation of antigen specific CD8+ cytotoxic T cells following immunization with soluble protein formulated with novel glycoside adjuvants

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.09.007

7 January 2021

Regulation of Isotype Immunoglobulin Production by Adjuvants in Vivo

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.09.007

7 January 2021

Potential of polymeric lamellar substrate particles (PLSP) as adjuvants for vaccines

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.09.007

7 January 2021

Continuous antigen delivery from controlled release implants induces significant and anamnestic immune responses.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.09.007

7 January 2021

Adjuvancy enhancement of muramyl dipeptide by modulating its release from a physicochemically modified matrix of ovalbumin microspheres. II. In vivo investigation

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.09.007

7 January 2021

Adjuvancy enhancement of muramyl dipeptide by modulating its release from a physicochemically modified matrix of ovalbumin microspheres. I. In vitro characterization.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.09.007

7 January 2021

Improved immune response from biodegradable polymer particles entrapping tetanus toxoid by use of different immunization protocol and adjuvants.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.09.007

7 January 2021

Protein release profiles and morphology of biodegradable microcapsules containing an oily core

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.09.007

7 January 2021

Controlled release microparticles as a single dose diphtheria toxoid vaccine: immunogenicity in small animal models

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.09.007

7 January 2021

Adjuvant effect of nonionic block polymer surfactants in humoral and cellular immunity

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.09.007

7 January 2021

Stable oil-in-water emulsions: preparation and use as vaccine vehicles for lipophilic adjuvants.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.09.007

7 January 2021

Relation between antigen release and immune response of oil adjuvanted vaccines in chickens

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.09.007

7 January 2021

Relationship between adjuvant activity and amphipathic structure of soyasaponins

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.09.007

7 January 2021

Mechanisms of stimulation of the immune response by aluminum adjuvants

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.09.007

7 January 2021

Dendritic cells acquire antigen from apoptotic cells and induce class I-restricted CTLs

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.09.007

7 January 2021

Immature dendritic cells phagocytose apoptotic cells via alphavbeta5 and CD36, and cross-present antigens to cytotoxic T lymphocytes

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.09.007

7 January 2021

Consequences of cell death: exposure to necrotic tumor cells, but not primary tissue cells or apoptotic cells, induces the maturation of immunostimulatory dendritic cells

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.09.007

7 January 2021

Antigen presentation and T cell stimulation by dendritic cells

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.09.007

7 January 2021

The CD8+ dendritic cell subset selectively endocytoses dying cells in culture and in vivo

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.09.007

7 January 2021

Identifiers

10.1016/J.VACCINE.2004.09.007

1 reference

Europe PubMed Central

PubMed publication ID

21 December 2017

http://europepmc.org/abstract/MED/15780450

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

21 December 2017

http://europepmc.org/abstract/MED/15780450

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q46393889&oldid=2109244474"